Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for KALV

Stock Name	Kalvista Pharmaceuticals Inc
Ticker	KALV(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US4834971032
LEI	529900Q7IDA3WUGRZA51

Show aggregate KALV holdings

News associated with KALV

Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Price Target at $26.43: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) has been given a consensus recommendation of “Buy” by the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year […] - 2025-09-16 02:32:43
Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Target Price at $26.29: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) has received an average recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective […] - 2025-08-22 02:58:49
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Bank of New York Mellon Corp: Bank of New York Mellon Corp boosted its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 5.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,530 shares of the specialty pharmaceutical company’s stock after purchasing an additional […] - 2025-08-01 04:26:58
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 5.5% After Analyst Upgrade: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) was up 5.5% during mid-day trading on Wednesday after JMP Securities raised their price target on the stock from $19.00 to $27.00. JMP Securities currently has a market outperform rating on the stock. KalVista Pharmaceuticals traded as high as $15.64 and last traded at $15.77. Approximately 354,539 […] - 2025-07-10 02:19:15
KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 52-Week High on Analyst Upgrade: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday after Leerink Partners raised their price target on the stock from $18.00 to $20.00. Leerink Partners currently has an outperform rating on the stock. KalVista Pharmaceuticals traded as high as $15.91 and last traded at […] - 2025-07-08 03:06:43
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Price Target from Analysts: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have been given an average recommendation of “Buy” by the eight research firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […] - 2025-07-03 02:21:03
Stocks Rally as Iran Signals it Wants an End to Hostilities: The S&P 500 Index ($SPX ) (SPY ) is up +1.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.49%. June E-mini S&P futures (ESM25 ) are up +1.11%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 19:35:01
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained: The S&P 500 Index ($SPX ) (SPY ) is up +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM25 ) are up +0.91%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 18:33:15
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained: The S&P 500 Index ($SPX ) (SPY ) is up +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM25 ) are up +0.91%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 14:56:10
Stocks Rally as Iran Signals it Wants an End to Hostilities: The S&P 500 Index ($SPX ) (SPY ) is up +1.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.49%. June E-mini S&P futures (ESM25 ) are up +1.11%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 14:39:41
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained: The S&P 500 Index ($SPX ) (SPY ) is up +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM25 ) are up +0.91%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 14:34:20
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained: The S&P 500 Index ($SPX ) (SPY ) is up +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM25 ) are up +0.91%, and June E-mini Nasdaq futures (NQM25... - 2025-06-16 12:47:32
53,382 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Bought by Ameriprise Financial Inc.: Ameriprise Financial Inc. acquired a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) during the 4th quarter, HoldingsChannel reports. The fund acquired 53,382 shares of the specialty pharmaceutical company’s stock, valued at approximately $452,000. Several other institutional investors also recently modified their holdings of the business. SG Americas Securities LLC grew its stake […] - 2025-06-05 04:22:54
ProShare Advisors LLC Purchases Shares of 11,906 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): ProShare Advisors LLC purchased a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 11,906 shares of the specialty pharmaceutical company’s stock, valued at approximately $101,000. Other hedge funds and other institutional investors also recently […] - 2025-06-04 04:54:43
Biotech Stocks Facing FDA Decision In June 2025: (RTTNews) - As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. From January through May 2025, the U.S. regulatory agency has approved 13 novel drugs, a modest decline from the 16 approvals recorded during the same period in 2024. - 2025-05-30 06:02:12
Graham Capital Management L.P. Buys New Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): Graham Capital Management L.P. bought a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 10,479 shares of the specialty pharmaceutical company’s stock, valued at approximately $89,000. Several other large investors have also recently bought […] - 2025-05-20 05:10:56
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price […] - 2025-05-14 02:18:47
KalVista Pharmaceuticals (NASDAQ:KALV) and Verrica Pharmaceuticals (NASDAQ:VRCA) Critical Review: Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) and KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Profitability This table compares Verrica Pharmaceuticals and […] - 2025-05-13 03:14:46
Dimensional Fund Advisors LP Has $5.90 Million Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): Dimensional Fund Advisors LP grew its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 14.7% in the 4th quarter, Holdings Channel reports. The firm owned 696,037 shares of the specialty pharmaceutical company’s stock after acquiring an additional 89,001 shares during the quarter. Dimensional Fund Advisors LP’s holdings in KalVista Pharmaceuticals were […] - 2025-05-12 04:47:02
Legal & General Group Plc Acquires 1,494 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): Legal & General Group Plc boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 22.5% in the fourth quarter, Holdings Channel reports. The firm owned 8,144 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,494 shares during the period. Legal & General Group Plc’s holdings in KalVista […] - 2025-05-02 04:40:58
Marshall Wace LLP Purchases 103,072 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): Marshall Wace LLP boosted its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 691.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 117,978 shares of the specialty pharmaceutical company’s stock after acquiring an additional 103,072 shares during the period. […] - 2025-05-01 04:52:57
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc.: Corebridge Financial Inc. trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 17.9% during the fourth quarter, HoldingsChannel reports. The fund owned 16,945 shares of the specialty pharmaceutical company’s stock after selling 3,682 shares during the quarter. Corebridge Financial Inc.’s holdings in KalVista Pharmaceuticals were worth $144,000 as of its […] - 2025-04-15 05:06:51
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 8.3% – Should You Buy?: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) rose 8.3% on Monday . The stock traded as high as $11.74 and last traded at $11.60. Approximately 531,267 shares traded hands during mid-day trading, an increase of 35% from the average daily volume of 392,121 shares. The stock had previously closed at $10.71. Analyst […] - 2025-04-08 04:36:53
Intech Investment Management LLC Raises Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): Intech Investment Management LLC lifted its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 58.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,204 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,349 shares during the quarter. Intech […] - 2025-03-28 06:30:47
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Buy” from Analysts: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have earned an average recommendation of “Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 […] - 2025-03-27 04:55:16
AlphaQuest LLC Acquires 2,588 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): AlphaQuest LLC lifted its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 17.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 17,700 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,588 shares during the quarter. AlphaQuest LLC’s holdings in KalVista Pharmaceuticals were worth $150,000 at the end of […] - 2025-03-18 06:03:37
HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV): HC Wainwright reissued their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $20.00 price objective on the specialty pharmaceutical company’s stock. Several other equities research analysts have also weighed in on KALV. Bank of America began coverage on shares […] - 2025-03-17 04:12:56
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Sees Significant Drop in Short Interest: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,130,000 shares, a decrease of 6.1% from the January 15th total of 7,590,000 shares. Based on an average daily volume of 368,500 shares, […] - 2025-02-19 06:42:41
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Bought by SG Americas Securities LLC: SG Americas Securities LLC grew its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 10.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,508 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,319 shares […] - 2025-02-12 06:14:54
China Universal Asset Management Co. Ltd. Grows Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): China Universal Asset Management Co. Ltd. increased its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 24.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,329 shares of the specialty pharmaceutical company’s stock after buying an additional 2,043 shares […] - 2025-02-04 07:14:58

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) KALV holdings

Date	Number of KALV Shares Held	Base Market Value of KALV Shares	Local Market Value of KALV Shares	Change in KALV Shares Held	Change in KALV Base Value	Current Price per KALV Share Held	Previous Price per KALV Share Held
2026-01-15 (Thursday)	34,658	USD 518,484	USD 518,484	158	USD -7,296	USD 14.96	USD 15.24
2026-01-14 (Wednesday)	34,500	USD 525,780	USD 525,780	158	USD 12,711	USD 15.24	USD 14.94
2026-01-13 (Tuesday)	34,342	USD 513,069	USD 513,069	0	USD -49,796	USD 14.94	USD 16.39
2026-01-12 (Monday)	34,342	USD 562,865	USD 562,865	158	USD -11,426	USD 16.39	USD 16.8
2026-01-09 (Friday)	34,184	USD 574,291	USD 574,291	237	USD 37,249	USD 16.8	USD 15.82
2026-01-08 (Thursday)	33,947	USD 537,042	USD 537,042	0	USD -17,652	USD 15.82	USD 16.34
2026-01-07 (Wednesday)	33,947	USD 554,694	USD 554,694	158	USD 22,517	USD 16.34	USD 15.75
2026-01-06 (Tuesday)	33,789	USD 532,177	USD 532,177	0	USD 3,041	USD 15.75	USD 15.66
2026-01-05 (Monday)	33,789	USD 529,136	USD 529,136	0	USD 6,758	USD 15.66	USD 15.46
2026-01-02 (Friday)	33,789	USD 522,378	USD 522,378	79	USD -22,039	USD 15.46	USD 16.15

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of KALV by Blackrock for IE00BDZVHG35

Show aggregate share trades of KALV

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2026-01-15 BUY 158 15.435 14.700 14.773 USD 2,334 12.24
2026-01-14 BUY 158 15.660 14.785 14.872 USD 2,350 12.23
2026-01-12 BUY 158 16.770 15.385 15.524 USD 2,453 12.20
2026-01-09 BUY 237 18.990 16.010 16.308 USD 3,865 12.18
2026-01-07 BUY 158 16.790 15.800 15.899 USD 2,512 12.14
2026-01-02 BUY 79 16.454 15.330 15.442 USD 1,220 12.09
2025-12-30 BUY 79 16.117 15.005 15.116 USD 1,194 12.06
2025-12-23 SELL -948 16.295 15.550 15.625 USD -14,812 12.00 Loss of -3,439 on sale
2025-12-19 SELL -4,322 15.470 14.940 14.993 USD -64,800 11.96 Loss of -13,091 on sale
2025-12-17 SELL -450 16.000 14.700 14.830 USD -6,673 11.94 Loss of -1,302 on sale
2025-12-16 SELL -90 17.090 15.835 15.961 USD -1,436 11.92 Loss of -364 on sale
2025-12-15 BUY 180 17.300 16.570 16.643 USD 2,996 11.89
2025-12-11 BUY 3,440 17.090 16.420 16.487 USD 56,715 11.85
2025-12-04 BUY 1,640 16.800 14.300 14.550 USD 23,862 11.73
2025-12-02 BUY 1,230 13.940 13.280 13.346 USD 16,416 11.71
2025-11-28 BUY 82 14.510 14.025 14.073 USD 1,154 11.68
2025-11-26 BUY 249 14.410 13.193 13.314 USD 3,315 11.66
2025-11-26 BUY 249 14.410 13.193 13.314 USD 3,315 11.66
2025-11-25 BUY 415 13.520 13.140 13.178 USD 5,469 11.65
2025-11-24 BUY 83 13.710 13.060 13.125 USD 1,089 11.64
2025-11-20 SELL -328 14.190 13.010 13.128 USD -4,306 11.63 Loss of -492 on sale
2025-11-19 BUY 82 14.488 13.680 13.761 USD 1,128 11.62
2025-11-18 BUY 492 14.790 14.060 14.133 USD 6,953 11.60
2025-11-17 BUY 164 14.970 13.320 13.485 USD 2,212 11.58
2025-11-14 BUY 82 13.870 12.950 13.042 USD 1,069 11.57
2025-11-12 BUY 82 13.440 11.460 11.658 USD 956 11.56
2025-11-10 BUY 82 11.100 10.630 10.677 USD 876 11.56
2025-11-06 BUY 82 11.320 10.765 10.821 USD 887 11.57
2025-11-04 BUY 82 11.045 10.510 10.564 USD 866 11.58
2025-10-30 BUY 410 11.300 10.915 10.953 USD 4,491 11.59
2025-10-29 BUY 164 10.960 11.245 11.216 USD 1,840 11.59
2025-10-22 SELL -328 11.130 11.560 11.517 USD -3,778 11.60 Profit of 29 on sale
2025-10-20 BUY 164 11.540 11.550 11.549 USD 1,894 11.61
2025-10-17 BUY 409 11.100 11.280 11.262 USD 4,606 11.61
2025-10-15 BUY 648 11.940 12.060 12.048 USD 7,807 11.61
2025-10-03 BUY 574 11.850 11.930 11.922 USD 6,843 11.61
2025-10-02 BUY 82 11.750 12.125 12.088 USD 991 11.61
2025-09-30 BUY 164 12.180 12.360 12.342 USD 2,024 11.60
2025-09-26 BUY 164 12.400 12.475 12.468 USD 2,045 11.59
2025-09-25 BUY 164 12.095 12.480 12.441 USD 2,040 11.59
2025-09-18 BUY 89 13.880 13.910 13.907 USD 1,238 11.57
2025-09-17 BUY 267 13.380 13.925 13.871 USD 3,703 11.56
2025-07-17 SELL -174 16.010 16.200 16.181 USD -2,815 11.47 Loss of -820 on sale
2025-07-16 BUY 1,821 15.790 15.850 15.844 USD 28,852 11.44
2025-07-11 SELL -664 14.520 14.995 14.947 USD -9,925 11.37 Loss of -2,374 on sale
2025-07-02 BUY 4,565 11.780 12.000 11.978 USD 54,680 11.31
2025-06-25 BUY 166 11.680 12.070 12.031 USD 1,997 11.30
2025-06-11 BUY 166 13.460 14.510 14.405 USD 2,391 11.21
2025-06-10 BUY 166 14.210 14.870 14.804 USD 2,457 11.19
2025-06-04 SELL -84 13.540 13.570 13.567 USD -1,140 11.10 Loss of -208 on sale
2025-04-23 BUY 83 12.450 12.690 12.666 USD 1,051 10.73
2025-04-10 SELL -664 10.540 10.750 10.729 USD -7,124 10.62 Loss of -74 on sale
2025-04-08 SELL -83 10.320 11.830 11.679 USD -969 10.62 Loss of -88 on sale
2025-04-07 SELL -83 11.500 11.735 11.711 USD -972 10.61 Loss of -91 on sale
2025-04-04 SELL -420 10.710 11.280 11.223 USD -4,714 10.61 Loss of -258 on sale
2025-04-01 BUY 344 11.155 11.780 11.717 USD 4,031 10.60
2025-03-31 SELL -252 11.540 11.760 11.738 USD -2,958 10.58 Loss of -291 on sale
2025-03-21 BUY 1,915 11.890 12.220 12.187 USD 23,338 10.46
2025-03-14 SELL -1,248 12.600 12.630 12.627 USD -15,758 10.33 Loss of -2,868 on sale
2025-03-07 SELL -156 11.920 12.195 12.167 USD -1,898 10.19 Loss of -309 on sale
2025-03-04 SELL -78 11.270 11.520 11.495 USD -897 10.12 Loss of -107 on sale
2025-02-25 BUY 156 10.775 10.850 10.843 USD 1,691 10.05
2025-02-19 SELL -78 10.710 11.000 10.971 USD -856 10.02 Loss of -74 on sale
2025-02-13 BUY 234 9.530 9.550 9.548 USD 2,234 10.05
2025-02-12 BUY 78 9.330 9.470 9.456 USD 738 10.06
2025-02-11 BUY 312 9.270 9.300 9.297 USD 2,901 10.08
2024-12-30 SELL -390 8.390 8.520 8.507 USD -3,318 10.55 Profit of 796 on sale
2024-11-18 SELL -1,155 9.300 9.570 9.543 USD -11,022 11.50 Profit of 2,256 on sale
2024-11-08 SELL -77 11.410 11.410 11.410 USD -879 11.56 Profit of 12 on sale
2024-10-21 SELL -78 12.320 12.500 12.482 USD -974 0.00 Loss of -974 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2026-01-15	BUY	158	15.435	14.700	14.773	USD 2,334	12.24
2026-01-14	BUY	158	15.660	14.785	14.872	USD 2,350	12.23
2026-01-12	BUY	158	16.770	15.385	15.524	USD 2,453	12.20
2026-01-09	BUY	237	18.990	16.010	16.308	USD 3,865	12.18
2026-01-07	BUY	158	16.790	15.800	15.899	USD 2,512	12.14
2026-01-02	BUY	79	16.454	15.330	15.442	USD 1,220	12.09
2025-12-30	BUY	79	16.117	15.005	15.116	USD 1,194	12.06
2025-12-23	SELL	-948	16.295	15.550	15.625	USD -14,812	12.00 Loss of -3,439 on sale
2025-12-19	SELL	-4,322	15.470	14.940	14.993	USD -64,800	11.96 Loss of -13,091 on sale
2025-12-17	SELL	-450	16.000	14.700	14.830	USD -6,673	11.94 Loss of -1,302 on sale
2025-12-16	SELL	-90	17.090	15.835	15.961	USD -1,436	11.92 Loss of -364 on sale
2025-12-15	BUY	180	17.300	16.570	16.643	USD 2,996	11.89
2025-12-11	BUY	3,440	17.090	16.420	16.487	USD 56,715	11.85
2025-12-04	BUY	1,640	16.800	14.300	14.550	USD 23,862	11.73
2025-12-02	BUY	1,230	13.940	13.280	13.346	USD 16,416	11.71
2025-11-28	BUY	82	14.510	14.025	14.073	USD 1,154	11.68
2025-11-26	BUY	249	14.410	13.193	13.314	USD 3,315	11.66
2025-11-26	BUY	249	14.410	13.193	13.314	USD 3,315	11.66
2025-11-25	BUY	415	13.520	13.140	13.178	USD 5,469	11.65
2025-11-24	BUY	83	13.710	13.060	13.125	USD 1,089	11.64
2025-11-20	SELL	-328	14.190	13.010	13.128	USD -4,306	11.63 Loss of -492 on sale
2025-11-19	BUY	82	14.488	13.680	13.761	USD 1,128	11.62
2025-11-18	BUY	492	14.790	14.060	14.133	USD 6,953	11.60
2025-11-17	BUY	164	14.970	13.320	13.485	USD 2,212	11.58
2025-11-14	BUY	82	13.870	12.950	13.042	USD 1,069	11.57
2025-11-12	BUY	82	13.440	11.460	11.658	USD 956	11.56
2025-11-10	BUY	82	11.100	10.630	10.677	USD 876	11.56
2025-11-06	BUY	82	11.320	10.765	10.821	USD 887	11.57
2025-11-04	BUY	82	11.045	10.510	10.564	USD 866	11.58
2025-10-30	BUY	410	11.300	10.915	10.953	USD 4,491	11.59
2025-10-29	BUY	164	10.960	11.245	11.216	USD 1,840	11.59
2025-10-22	SELL	-328	11.130	11.560	11.517	USD -3,778	11.60 Profit of 29 on sale
2025-10-20	BUY	164	11.540	11.550	11.549	USD 1,894	11.61
2025-10-17	BUY	409	11.100	11.280	11.262	USD 4,606	11.61
2025-10-15	BUY	648	11.940	12.060	12.048	USD 7,807	11.61
2025-10-03	BUY	574	11.850	11.930	11.922	USD 6,843	11.61
2025-10-02	BUY	82	11.750	12.125	12.088	USD 991	11.61
2025-09-30	BUY	164	12.180	12.360	12.342	USD 2,024	11.60
2025-09-26	BUY	164	12.400	12.475	12.468	USD 2,045	11.59
2025-09-25	BUY	164	12.095	12.480	12.441	USD 2,040	11.59
2025-09-18	BUY	89	13.880	13.910	13.907	USD 1,238	11.57
2025-09-17	BUY	267	13.380	13.925	13.871	USD 3,703	11.56
2025-07-17	SELL	-174	16.010	16.200	16.181	USD -2,815	11.47 Loss of -820 on sale
2025-07-16	BUY	1,821	15.790	15.850	15.844	USD 28,852	11.44
2025-07-11	SELL	-664	14.520	14.995	14.947	USD -9,925	11.37 Loss of -2,374 on sale
2025-07-02	BUY	4,565	11.780	12.000	11.978	USD 54,680	11.31
2025-06-25	BUY	166	11.680	12.070	12.031	USD 1,997	11.30
2025-06-11	BUY	166	13.460	14.510	14.405	USD 2,391	11.21
2025-06-10	BUY	166	14.210	14.870	14.804	USD 2,457	11.19
2025-06-04	SELL	-84	13.540	13.570	13.567	USD -1,140	11.10 Loss of -208 on sale
2025-04-23	BUY	83	12.450	12.690	12.666	USD 1,051	10.73
2025-04-10	SELL	-664	10.540	10.750	10.729	USD -7,124	10.62 Loss of -74 on sale
2025-04-08	SELL	-83	10.320	11.830	11.679	USD -969	10.62 Loss of -88 on sale
2025-04-07	SELL	-83	11.500	11.735	11.711	USD -972	10.61 Loss of -91 on sale
2025-04-04	SELL	-420	10.710	11.280	11.223	USD -4,714	10.61 Loss of -258 on sale
2025-04-01	BUY	344	11.155	11.780	11.717	USD 4,031	10.60
2025-03-31	SELL	-252	11.540	11.760	11.738	USD -2,958	10.58 Loss of -291 on sale
2025-03-21	BUY	1,915	11.890	12.220	12.187	USD 23,338	10.46
2025-03-14	SELL	-1,248	12.600	12.630	12.627	USD -15,758	10.33 Loss of -2,868 on sale
2025-03-07	SELL	-156	11.920	12.195	12.167	USD -1,898	10.19 Loss of -309 on sale
2025-03-04	SELL	-78	11.270	11.520	11.495	USD -897	10.12 Loss of -107 on sale
2025-02-25	BUY	156	10.775	10.850	10.843	USD 1,691	10.05
2025-02-19	SELL	-78	10.710	11.000	10.971	USD -856	10.02 Loss of -74 on sale
2025-02-13	BUY	234	9.530	9.550	9.548	USD 2,234	10.05
2025-02-12	BUY	78	9.330	9.470	9.456	USD 738	10.06
2025-02-11	BUY	312	9.270	9.300	9.297	USD 2,901	10.08
2024-12-30	SELL	-390	8.390	8.520	8.507	USD -3,318	10.55 Profit of 796 on sale
2024-11-18	SELL	-1,155	9.300	9.570	9.543	USD -11,022	11.50 Profit of 2,256 on sale
2024-11-08	SELL	-77	11.410	11.410	11.410	USD -879	11.56 Profit of 12 on sale
2024-10-21	SELL	-78	12.320	12.500	12.482	USD -974	0.00 Loss of -974 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of KALV

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	206,700	0	312,451	66.2%
2025-09-18	106,199	0	217,399	48.8%
2025-09-17	100,446	0	161,758	62.1%
2025-09-16	200,973	2,500	330,072	60.9%
2025-09-15	132,995	571	274,741	48.4%
2025-09-12	491,715	32,572	973,258	50.5%
2025-09-11	725,694	14,624	1,135,070	63.9%
2025-09-10	71,389	0	381,253	18.7%
2025-09-09	156,952	0	445,092	35.3%
2025-09-08	256,661	2,800	530,266	48.4%
2025-09-05	152,810	1,648	357,612	42.7%
2025-09-04	245,996	0	580,692	42.4%
2025-09-03	197,515	0	776,027	25.5%
2025-09-02	176,150	0	408,112	43.2%
2025-08-29	100,610	0	148,054	68.0%
2025-08-28	80,479	0	135,744	59.3%
2025-08-27	67,559	0	106,061	63.7%
2025-08-26	121,989	0	170,445	71.6%
2025-08-25	143,129	1,730	191,901	74.6%
2025-08-22	86,357	2,206	174,732	49.4%
2025-08-21	99,833	75	159,092	62.8%
2025-08-20	113,403	0	182,673	62.1%
2025-08-19	126,996	2,870	196,519	64.6%
2025-08-18	286,398	0	390,856	73.3%
2025-08-15	133,756	600	239,987	55.7%
2025-08-14	276,630	0	366,914	75.4%
2025-08-13	133,263	0	225,869	59.0%
2025-08-12	88,776	0	158,553	56.0%
2025-08-11	78,111	300	127,291	61.4%
2025-08-08	126,588	800	213,003	59.4%
2025-08-07	103,660	100	200,455	51.7%
2025-08-06	119,011	3	226,300	52.6%
2025-08-05	110,819	420	196,225	56.5%
2025-08-04	93,168	0	205,318	45.4%
2025-08-01	115,638	0	232,982	49.6%
2025-07-31	130,335	0	211,779	61.5%
2025-07-30	178,343	0	324,541	55.0%
2025-07-29	227,270	0	421,978	53.9%
2025-07-28	272,489	4,072	819,277	33.3%
2025-07-25	88,927	0	488,233	18.2%
2025-07-24	80,047	440	229,916	34.8%
2025-07-23	245,140	0	575,374	42.6%
2025-07-22	134,483	655	231,990	58.0%
2025-07-21	119,613	15,831	216,134	55.3%
2025-07-18	142,528	2,461	517,060	27.6%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE